Drug details

Leqvio (inclisiran injection)

type of PCSK9 Inhibitors

Leqvio (inclisiran) is a small interfering RNA (siRNA) directed to PCSK9 (proprotein convertase subtilisin kexin type 9) mRNA indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of low-density lipoprotein cholesterol (LDL-C).

This drug may have the following side effects:

• diarrhea,
• joint pain,
• urinary tract infection (UTI),
• injection site reactions (pain, redness, rash),
• bronchitis,
• pain in extremities, and
• shortness of breath.

The following drugs are related to Leqvio, either as a replacement or used together:

• Praluent (alirocumab for solution for subcutaneous injection)
• Altoprev (lovastatin extended-release tablets)
• Caduet (amlodipine besylate, atorvastatin calcium)
• Antara (fenofibrate)
• Lipitor (atorvastatin calcium)
• Nexlizet (bempedoic acid and ezetimibe tablets)
• Nexletol (bempedoic acid tablets, for oral use)
• Prevalite (cholestyramine for oral suspension, us)
• Welchol (colesevelam hcl)
• Crestor (rosuvastatin calcium)
• Repatha (evolocumab injection, for subcutaneous injection)
• Vytorin (ezetimibe and simvastatin)
• Zetia (ezetimibe tablets)
• Lipofen (fenofibrate)
• Triglide (fenofibrate)
• Tricor (fenofibrate)
• Fenoglide (fenofibrate tablets)
• Fibricor (fenofibric acid)
• Trilipix (fenofibric acid capsules)
• Lescol (fluvastatin sodium)
• Lescol XL (fluvastatin sodium extended-release tablets)
• Livalo (pitavastatin)
• Niacor (niacin tablets)
• Pravachol (pravastatin sodium)
• Zocor (simvastatin)